An original article titled, “Real-World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP-1 Receptor Agonists Versus FDA-Approved AUD Medications,” was published in Alimentary Pharmacology & Therapeutics by authors Amir Gougol, MD; Paul Kwo, MD; William Pike, MD; Mehdi Farokhnia, MD; Gavin Hui, MD; Saurabh Gombar, MD; and Babak Mirminachi, MD. The authors are affiliated with Stanford University, Eli Lilly and Company, Atropos Health, and the University of Pittsburgh Medical Center.
Short Summary:
Metabolic dysfunction (MetD) and alcohol use disorder (AUD) frequently coexist as synergistic risk factors for steatotic liver disease, yet treatment strategies that address both conditions simultaneously remain understudied. In this retrospective cohort study, the authors examine whether GLP-1 receptor agonists (GLP-1RAs) — commonly used to treat obesity and type 2 diabetes — may offer benefits for AUD outcomes compared to currently FDA-approved AUD pharmacotherapies in patients with concurrent MetD and AUD.